ESALY - Catalyst Pharma gains U.S. rights to Eisai epilepsy drug Fycompa
- Catalyst Pharmaceuticals ( NASDAQ: CPRX ) will acquire the U.S. rights to Eisai's ( OTCPK:ESALY ) epilepsy drug Fycompa (perampanel) as well as a period to review and negotiate the acquisition of a rare epilepsy asset in the Japanese drugmaker's pipeline.
- Terms calls for Eisai ( OTCPK:ESALY ) to receive a $160M upfront payment, and is eligible future milestones and royalties.
- Catalyst's ( CPRX ) only marketed drug in the US is Firdapse (amifampridine) for Lambert-Eaton myasthenic syndrome, a rare neuromuscular disease.
- Read why Seeking Alpha contributor Alexander Carchidi is bullish on Catalyst ( CPRX ).
For further details see:
Catalyst Pharma gains U.S. rights to Eisai epilepsy drug Fycompa